A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)

NCT03311854 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Macrophage Activation Syndrome
Lymphohistiocytosis, Hemophagocytic
Arthritis, Juvenile
Adult Onset Still Disease

Interventions

DRUG: Emapalumab

Sponsor

Swedish Orphan Biovitrum